

Specialty Guideline Management

Nuplazid

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Nuplazid	pimavanserin

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-approved Indications¹

Nuplazid is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

All other indications are considered experimental/investigational and not medically necessary.

Coverage Criteria

Parkinson's disease¹⁻³

Authorization of 6 months may be granted for treatment of hallucinations and delusions associated with Parkinson's disease psychosis when the member has mild or no cognitive impairment as determined by the physician's clinical diagnosis and/or cognitive impairment screening tests (e.g., Mini-Mental Status

Examination [MMSE], Montreal Cognitive Assessment [MoCA]).

Continuation of Therapy

Authorization of 12 months may be granted for continued treatment of hallucinations and delusions associated with Parkinson's disease psychosis when the member has experienced improvement in psychotic symptoms (hallucinations and/or delusions) since starting therapy.

References

1. Nuplazid [package insert]. San Diego, CA: Acadia Pharmaceuticals, Inc.; September 2023.
2. Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomized, placebo-controlled phase 3 trial. [published correction appears in Lancet. 2014 Jul 5;384(9937):28]. Lancet. 2014; 383(9916):533-540. doi:10.1016/S0140-6736(13)62106-6
3. Hoops S, Nazem S, Siderowf AD, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009; 73 (21): 1738-1745. doi:10.1212/WNL.0b013e3181c34b47